Anaheim Bio: Funding, Investors & Team (Nov 2026)
Anaheim Bio develops small molecule therapies to treat calcium pyrophosphate deposition disease (CPPD) at its source.
Anaheim Bio has raised $44.9M across 1 funding round on record, the most recent a Series A of $44.9M announced in Nov 2026.
That round is above the $3.3M median round size for The Netherlands companies tracked on FundedIQ over the last two years.
Anaheim Bio Company Profile and Key Stats
Latest funding round on record: Nov 2026.
Anaheim Bio Funding Rounds
Anaheim Bio Investors
6 investors are recorded in total; the 5 named above are those the record identifies.
Anaheim Bio Funding in Context
Anaheim Bio's latest round of $44.9M is above the median round in The Netherlands. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Anaheim Bio in Biotechnology and Leiden
Companies Similar to Anaheim Bio
Caspian Therapeutics is a biotechnology company developing menin inhibitors to treat diabetes.
Genta Kyushu Bio develops precision neuro circuit therapies for CNS and eye diseases via optogenetics and…
Photon Bridge develops multi-wavelength DWDM light engines and photonic integration platforms for AI data…
ParkMundo, the most comprehensive platform for airport parking services.
Operating system for class-based sports
Booomtag provides NFC, RFID, and QR-based product tagging with a cloud platform for product registration and…
RougeTx is a biotech developing first-in-class small-molecule therapies for vascular diseases caused by…
Duqu provides short-term business financing by advancing money on outstanding business-to-business invoices.
Euclyd develops AI infrastructure designed to make advanced AI computing more efficient and scalable.
Persistent, forkable and suspendable virtual machines for agents and agentic workloads.
UCANACT is a digital assistive technology paired with wearables or implants to give motor-disabled…
Custodea is a data platform that brings business data from multiple software systems into one private data…
Anaheim Bio Funding FAQs
What does Anaheim Bio do?
Anaheim Bio develops small molecule therapies to treat calcium pyrophosphate deposition disease (CPPD) at its source.
How much funding has Anaheim Bio raised?
Anaheim Bio has raised $44.9M across 1 round on record. The most recent is a Series A of $44.9M announced in Nov 2026.
When did Anaheim Bio last raise funding?
Anaheim Bio's most recent funding round on record is a Series A of $44.9M, announced in Nov 2026.
Who has invested in Anaheim Bio?
Investors on record for Anaheim Bio include RTW Investments, Novartis, Frazier Life Sciences, Droia Ventures, Thuja Capital. FundedIQ records 6 investors in total.
Where is Anaheim Bio headquartered?
Anaheim Bio is based in Leiden, The Netherlands.
When was Anaheim Bio founded?
Anaheim Bio was founded in 2026.
About FundedIQ's Anaheim Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Anaheim Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.